These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 912511)

  • 1. 1alpha-Hydroxycholecalciferol in renal osteodystrophy.
    Pierides AM; Ellis HA; Ward MK; Simpson W; Kerr DN
    Calcif Tissue Res; 1977 May; 22 Suppl():105-11. PubMed ID: 912511
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization.
    Fournier A; Bordier P; Gueris J; Sebert JL; Marie P; Ferrière C; Bedrossian J; DeLuca HF
    Kidney Int; 1979 Feb; 15(2):196-204. PubMed ID: 513484
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of renal osteodystrophy with 1alpha-hydroxycholecalciferol (1alpha-OH-D3) in conjunction with a high dialysate calcium.
    Winney RJ; Bone JM; Anderson TJ; Robson JS
    Calcif Tissue Res; 1977 May; 22 Suppl():94-100. PubMed ID: 912593
    [No Abstract]   [Full Text] [Related]  

  • 4. The treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.
    Junor BJ; Catto GR; Macleod M
    Calcif Tissue Res; 1977 May; 22 Suppl():112-6. PubMed ID: 912512
    [No Abstract]   [Full Text] [Related]  

  • 5. 1alpha-Hydroxycholecalciferol in children with renal osteodystrophy.
    Postlethwaite RJ; Houston IB
    Calcif Tissue Res; 1977 May; 22 Suppl():371-5. PubMed ID: 912549
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of 6 months therapy with 1,25 (OH)2D3 on bone disease of dialysis patients.
    Malluche HH; Goldstein DA; Massry SG
    Contrib Nephrol; 1980; 18():98-104. PubMed ID: 7353383
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term treatment of uraemic osteodystrophy with 1-alpha-hydroxycholecalciferol.
    Nielsen SP; Binderup E; Godtfredsen WO; Jensen H; Ladefoged J
    Proc Eur Dial Transplant Assoc; 1976; 12():221-6. PubMed ID: 935114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Renal osteodystrophy in two children : a comparison of the effects of 1 alpha-hydroxycholecalciferol (author's transl)].
    Chantraine JM; Davin JC; Lambrechts L; Heynen G
    Ann Endocrinol (Paris); 1979; 40(2):161-2. PubMed ID: 475307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in renal bone disease.
    Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; De Luca HF
    Calcif Tissue Res; 1976 Aug; 21 Suppl():226-35. PubMed ID: 782662
    [No Abstract]   [Full Text] [Related]  

  • 10. 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease.
    Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; de Luca HF
    Proc Eur Dial Transplant Assoc; 1976; 12():227-36. PubMed ID: 935115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease.
    Pierides AM; Ellis HA; Simpson W; Cook D; Kerr DN
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():109s-116s. PubMed ID: 606409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1alpha-hydroxycholecalciferol: a promising therapeutic approach for renal osteodystrophy.
    Gotloib L; Mines M; Mazur Y; Sklan D; Garmizo AL; Jancu J; Israeli M; Malul M
    Isr J Med Sci; 1978 Jul; 14(7):731-5. PubMed ID: 681163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of the use of newer analogs of vitamin D in the management of renal osteodystrophy.
    Coburn JW; Brickman AS
    Adv Exp Med Biol; 1978; 103():473-86. PubMed ID: 362852
    [No Abstract]   [Full Text] [Related]  

  • 14. 1-alpha-hydroxycholecalciferol for renal osteodystrophy.
    Brownjohn AM; Goodwin FJ; Hately W; Marsh FP; O'Riordan JL; Papapoulos SE
    Br Med J; 1977 Sep; 2(6089):721-3. PubMed ID: 912269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypophosphataemia and osteomalacia in haemodialysis patients not taking phosphate binders.
    Ahmed KY; Varghese Z; Meinhard EA; Baillod RA; Skinner RK; Wills MR; Moorhead JF
    Adv Exp Med Biol; 1977; 81():581-90. PubMed ID: 899942
    [No Abstract]   [Full Text] [Related]  

  • 16. Influence of long-term oral 1,25-dihydroxyvitamin D in childhood renal osteodystrophy.
    Chesney RW; Hamstra A; Jax DK; Mazess RB; DeLuca HF
    Contrib Nephrol; 1980; 18():55-71. PubMed ID: 7353380
    [No Abstract]   [Full Text] [Related]  

  • 17. [Long-term effects of a combination of 25-hydroxycholecalciferol and 1-alpha-hydroxycholecalciferol on osteodystrophy in chronic hemodialysis patients].
    Sebert JL; Marie A; Kuntz D; Marie P; Gueris J; Smadja A; Fournier A; Quichaud J
    Rev Rhum Mal Osteoartic; 1981; 48(7-9):535-41. PubMed ID: 7291931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
    Massry SG; Goldstein DA; Malluche HH
    Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
    Fournier A; Oprisiu R; Hottelart C; Yverneau PH; Ghazali A; Atik A; Hedri H; Said S; Sechet A; Rasolombololona M; Abighanem O; Sarraj A; El Esper N; Moriniere P; Boudailliez B; Westeel PF; Achard JM; Pruna A
    Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.